Clinical trial

Exemestane Plus Everolimus for Hormone-receptor Positive Metastatic Breast Cancer

NCT02025712

Drugs and interventions used in this trial

2 registered

These interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.

Search this trial's interventions

DRUG · Mapped RxNorm record Exemestane Normalized identity: exemestaneView linked drug · Find medicine records · Find other trials using this name

DRUG · Mapped RxNorm record Everolimus Normalized identity: everolimusView linked drug · Find medicine records · Find other trials using this name

Study at a glance

Registry-backed

Exemestane Plus Everolimus for Hormone-receptor Positive Metastatic Breast Cancer

Design: INTERVENTIONAL · Status: UNKNOWN · Phase: PHASE2

Read study objectives, eligibility and outcome measures at ClinicalTrials.gov

StatusUNKNOWN

Study typeINTERVENTIONAL

Start dateUnknown

PhasePHASE2

Conditions

Hormone Receptor Positive Malignant Neoplasm of Breastunresolved

Interventions

ExemestaneDRUG · verified · RxNorm: exemestane

EverolimusDRUG · verified · RxNorm: everolimus

Sponsors & collaborators

Organisation for Oncology and Translational Researchlead sponsor

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT02025712 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.